Kübra Demi̇r Önder
Kübra Demi̇r Önder has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Ayşegül Seremet Keskin
Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, University of Health Sciences, Antalya 07050, Turkey
7 shared publications - Derya Seyman
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Antalya Training and Research Hospital, Antalya 07100, Türkiye
3 shared publications - Filiz Kizilateş
Department of Infectious Diseases and Clinical Microbiology Private Anatolia Hospital Antalya Turkey
3 shared publications - Mustafa Deniz
Department of Infectious Diseases and Clinical Microbiology, Antalya City Hospital, Göçerler, 5379. Street, Kepez, Antalya, 07080, Turkey.
3 shared publications - Fatma Yekta Urkmez
Kirikkale Yuksek Ihtisas Hospital
2 shared publications - Hasan Selçuk Özger
Koç University Faculty of Medicine, Department of Infectious Diseases, İstanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Galenos Yayinevi in Hamidiye Medical Journal
Adult Salmonella Infections: A 10-Year Clinical Experience in a Tertiary Care Center
Background Salmonella infections are an important cause of foodborne illness and may present with a broad clinical spectrum, ranging from mild gastroenteritis to invasive systemic infections. This study aimed to evaluate the epidemiological, clinical, and microbiological characteristics of…
- 11 November 2026
- Published by Galenos Yayinevi in Hamidiye Medical Journal
Open AccessAdult Salmonella Infections: A 10-Year Clinical Experience in a Tertiary Care Center
Background Salmonella infections are an important cause of foodborne illness and may present with a broad clinical spectrum, ranging from mild gastroenteritis to invasive systemic infections. This study aimed to evaluate the epidemiological, clinical, and microbiological characteristics of…
- Open Access
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 58-65
Predictors for Publication of Specialty Theses in the Field of Infectious Diseases and Clinical Microbiology
The residency program of infectious diseases and clinical microbiology (IDCM) in Türkiye was started in 1983 by adopting the name IDCM. The IDCM program in Türkiye is a five-year program, including related clinical rotations. Presenting a thesis at the end of this program is mandatory. The first specialty thesis in the field of IDCM was
- 27 March 2025
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 7 (1) , 58-65
Open AccessPredictors for Publication of Specialty Theses in the Field of Infectious Diseases and Clinical Microbiology
The residency program of infectious diseases and clinical microbiology (IDCM) in Türkiye was started in 1983 by adopting the name IDCM. The IDCM program in Türkiye is a five-year program, including related clinical rotations. Presenting a thesis at the end of this program is mandatory. The first specialty thesis in the field of IDCM was
- Open Access
- 29 December 2023
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 5 (4) , 376-379
Clinical Entity Mimicking Infectious Cellulitis: Eosinophilic Cellulitis (Wells’ Syndrome)
Eosinophilic cellulitis (EC) is a rare inflammatory skin condition with fewer than 200 documented cases in the medical literature. There are only a limited number of case reports available from our country. The prevalence and incidence of EC are unknown. The disease is characterized by pruritic, non-purulent, erythematous plaques (...)
- 29 December 2023
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 5 (4) , 376-379
Open AccessClinical Entity Mimicking Infectious Cellulitis: Eosinophilic Cellulitis (Wells’ Syndrome)
Eosinophilic cellulitis (EC) is a rare inflammatory skin condition with fewer than 200 documented cases in the medical literature. There are only a limited number of case reports available from our country. The prevalence and incidence of EC are unknown. The disease is characterized by pruritic, non-purulent, erythematous plaques (...)
- Open Access
- 16 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35071
Should Preventive Antifungal Treatment Be Given to Patients With Abdominal Contamination in the Intensive Care Unit?
Background Intra-abdominal contamination is a critical risk factor for candidemia. Because of the high mortality of candidemia and delayed results of cultures, preventive antifungal (AF) treatment can be administered. Especially in the intensive care unit (ICU), it may be necessary to determine the preventive AF approach due to the poor clinical condition of the patients. However, this practice is not standard among clinicians, and it is controversial whether it is beneficial or not. This study aimed to evaluate the effects of different AF treatment approaches (prophylactic, empirical, and culture-directed) on mortality, development of candidemia, and length of hospital stay in these patients. The primary outcome of the study was mortality, and the secondary outcomes were the development of candidemia and length of hospital stay. Methodology This is a retrospective, single-center, cohort study. Adult patients who were hospitalized in the ICU with the diagnosis of intra-abdominal contamination between January 1, 2017, and December 31, 2020, were reviewed retrospectively from electronic hospital records and Infectious Diseases ICU patient follow-up forms. Age, gender, comorbid diseases, the reason for hospitalization, history of surgical operation, surgical procedure type, length of hospital stay, culture results of blood and intraoperative intra-abdominal samples (pus, peritoneal fluid, abscess), type of AF agents, and mortality status of the patients were recorded. Furthermore, white blood cell (WBC) count, platelet count, C-reactive protein (CRP) level, procalcitonin (PCT) level, and serum albumin levels in blood samples taken on three different days (the day of diagnosis, the day of operation, and the day of candidemia) were examined. The patients were grouped as without AF, receiving prophylactic AF, receiving empirical AF, and receiving culture-directed AF. Additionally, the study population was evaluated by dividing it into two groups, namely, those who developed candidemia and those who did not. The patients were evaluated regarding the development of candidemia, AF treatment approach, length of hospital stay, and mortality. Results A total of 196 patients were included in the study. Candidemia was determined in 31.6% of the patients. Candidemia was more common in patients with a history of previous surgery and presenting with acute abdominal pain than other causes. It was determined that 70% of the patients who developed candidemia had perforation, with the most common being colonic perforation. The hospital stay was longer in patients with candidemia than without candidemia (47.9 vs. 22.4 days; p < 0.001). When empirical and prophylactic AF recipients were compared, there was no difference in mortality and length of hospital stay. Prolongation of the time to empirical treatment after perforation/leak was associated with increased candidemia (p = 0.004). Furthermore, patients with a waiting time of ≥4.5 days until surgical operation were at a higher risk of developing candidemia. Conclusions Although the study did not demonstrate a difference in terms of reducing mortality, it was concluded that preventive AF therapy can be administered to reduce the risk of candidemia and hospitalization duration, especially in patients with a history of previous surgical operations and abdominal contamination with a prolonged waiting period until the surgical operation.
- 16 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35071
Open AccessShould Preventive Antifungal Treatment Be Given to Patients With Abdominal Contamination in the Intensive Care Unit?
Background Intra-abdominal contamination is a critical risk factor for candidemia. Because of the high mortality of candidemia and delayed results of cultures, preventive antifungal (AF) treatment can be administered. Especially in the intensive care unit (ICU), it may be necessary to determine the preventive AF approach due to the poor clinical condition of the patients. However, this practice is not standard among clinicians, and it is controversial whether it is beneficial or not. This study aimed to evaluate the effects of different AF treatment approaches (prophylactic, empirical, and culture-directed) on mortality, development of candidemia, and length of hospital stay in these patients. The primary outcome of the study was mortality, and the secondary outcomes were the development of candidemia and length of hospital stay. Methodology This is a retrospective, single-center, cohort study. Adult patients who were hospitalized in the ICU with the diagnosis of intra-abdominal contamination between January 1, 2017, and December 31, 2020, were reviewed retrospectively from electronic hospital records and Infectious Diseases ICU patient follow-up forms. Age, gender, comorbid diseases, the reason for hospitalization, history of surgical operation, surgical procedure type, length of hospital stay, culture results of blood and intraoperative intra-abdominal samples (pus, peritoneal fluid, abscess), type of AF agents, and mortality status of the patients were recorded. Furthermore, white blood cell (WBC) count, platelet count, C-reactive protein (CRP) level, procalcitonin (PCT) level, and serum albumin levels in blood samples taken on three different days (the day of diagnosis, the day of operation, and the day of candidemia) were examined. The patients were grouped as without AF, receiving prophylactic AF, receiving empirical AF, and receiving culture-directed AF. Additionally, the study population was evaluated by dividing it into two groups, namely, those who developed candidemia and those who did not. The patients were evaluated regarding the development of candidemia, AF treatment approach, length of hospital stay, and mortality. Results A total of 196 patients were included in the study. Candidemia was determined in 31.6% of the patients. Candidemia was more common in patients with a history of previous surgery and presenting with acute abdominal pain than other causes. It was determined that 70% of the patients who developed candidemia had perforation, with the most common being colonic perforation. The hospital stay was longer in patients with candidemia than without candidemia (47.9 vs. 22.4 days; p < 0.001). When empirical and prophylactic AF recipients were compared, there was no difference in mortality and length of hospital stay. Prolongation of the time to empirical treatment after perforation/leak was associated with increased candidemia (p = 0.004). Furthermore, patients with a waiting time of ≥4.5 days until surgical operation were at a higher risk of developing candidemia. Conclusions Although the study did not demonstrate a difference in terms of reducing mortality, it was concluded that preventive AF therapy can be administered to reduce the risk of candidemia and hospitalization duration, especially in patients with a history of previous surgical operations and abdominal contamination with a prolonged waiting period until the surgical operation.
- Open Access
- 1 January 2023
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 16 (1) , 1
Üçüncü basamak bir hastanede COVID-19 tanılı hastalarda remdesivir deneyimi
Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR and/or thoracic computed tomography (CT) results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen (79.2%) of the patients were male and 5 (20.8%) were female. Remdesivir initiation time was 8.4±2.6 days from the onset of symptoms and 6±2.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients (78.2%) in the intensive care unit (ICU). 14 (60.8%) needed a mechanical ventilator. Post-treatment follow-up showed that 15 (65.2%) recovered, and 8 (34.8%) resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.
- 1 January 2023
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 16 (1) , 1
Open AccessÜçüncü basamak bir hastanede COVID-19 tanılı hastalarda remdesivir deneyimi
Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR and/or thoracic computed tomography (CT) results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen (79.2%) of the patients were male and 5 (20.8%) were female. Remdesivir initiation time was 8.4±2.6 days from the onset of symptoms and 6±2.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients (78.2%) in the intensive care unit (ICU). 14 (60.8%) needed a mechanical ventilator. Post-treatment follow-up showed that 15 (65.2%) recovered, and 8 (34.8%) resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.
- Open Access
- 28 August 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 5437850
Investigation of Effect of the Colistin Loading Dosage on the clinical, Microbiological, and Laboratory Results in Acinetobacter baumannii Ventilator‐Associated Pneumonia /Pneumonia
Introduction and Objectives. The comparative efficacy of colistin with a loading dose (LD) and without LD remains unknown. We aimed at assessing the efficacy and safety of colistin with LD in patients with multidrug resistance (MDR) Acinetobacter baumannii ventilator‐associated pneumonia (VAP) or pneumonia, compared with colistin without LD. Materials and Methods. Adult patients administered colistin with and without LD for MDR Acinetobacter baumannii VAP/pneumonia in intensive care units (ICUs) in a tertiary teaching hospital between 1 January 2018 and 31 December 2019 were included in this retrospective cohort study. The primary endpoint was an assessment of clinical and microbiological success between treatment groups. Secondary endpoints included 14‐ and 30‐day mortality and development of nephrotoxicity. Results. A total of 101 patients were included (colistin with LD, n = 57; colistin without LD, n = 44). No significant difference in clinical success was observed between groups (73.7% versus 77.3%; p = 0.670). In patients receiving colistin with LD, the microbiological success rate increased from 65.9% to 71.9%, but there was no statistically significantly difference (p = 0.510). In terms of using combination therapies with carbapeneme and/or tigecycline, there was no significant difference between treatment groups (p = 0.30). The rates of 14‐ and 30‐day mortality were similar between groups. The colistin with LD group had a higher rate of nephrotoxicity compared to the other group (52.6% versus 20.5% p = 0.001). The clinical and microbiological response times were found significantly higher in the colistin with LD group (p = 0.001; p = 0.017). Conclusion. Colistin with LD was associated with a higher risk of nephrotoxicity and was not related to clinical success, microbiological success, and prolonged survival. Randomized comparative studies are needed to confirm the efficacy of LD colistin regimen on MDR Acinetobacter infection.
- 28 August 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 5437850
Open AccessInvestigation of Effect of the Colistin Loading Dosage on the clinical, Microbiological, and Laboratory Results in Acinetobacter baumannii Ventilator‐Associated Pneumonia /Pneumonia
Introduction and Objectives. The comparative efficacy of colistin with a loading dose (LD) and without LD remains unknown. We aimed at assessing the efficacy and safety of colistin with LD in patients with multidrug resistance (MDR) Acinetobacter baumannii ventilator‐associated pneumonia (VAP) or pneumonia, compared with colistin without LD. Materials and Methods. Adult patients administered colistin with and without LD for MDR Acinetobacter baumannii VAP/pneumonia in intensive care units (ICUs) in a tertiary teaching hospital between 1 January 2018 and 31 December 2019 were included in this retrospective cohort study. The primary endpoint was an assessment of clinical and microbiological success between treatment groups. Secondary endpoints included 14‐ and 30‐day mortality and development of nephrotoxicity. Results. A total of 101 patients were included (colistin with LD, n = 57; colistin without LD, n = 44). No significant difference in clinical success was observed between groups (73.7% versus 77.3%; p = 0.670). In patients receiving colistin with LD, the microbiological success rate increased from 65.9% to 71.9%, but there was no statistically significantly difference (p = 0.510). In terms of using combination therapies with carbapeneme and/or tigecycline, there was no significant difference between treatment groups (p = 0.30). The rates of 14‐ and 30‐day mortality were similar between groups. The colistin with LD group had a higher rate of nephrotoxicity compared to the other group (52.6% versus 20.5% p = 0.001). The clinical and microbiological response times were found significantly higher in the colistin with LD group (p = 0.001; p = 0.017). Conclusion. Colistin with LD was associated with a higher risk of nephrotoxicity and was not related to clinical success, microbiological success, and prolonged survival. Randomized comparative studies are needed to confirm the efficacy of LD colistin regimen on MDR Acinetobacter infection.
- Open Access
- 22 August 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (3) , 126-132
Evaluation of the Association Between Ct Value of SARS-CoV-2 PCR with Disease Progression and Mortality
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Methods: Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-related symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for mechanical ventilation (MV), and mortality) were reviewed retrospectively. Results: 117 patients were included in the study. The mean Ct value was 22.37±4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24; there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and ≥23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion: Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID-19 patients in this presented study.
- 22 August 2022
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 35 (3) , 126-132
Open AccessEvaluation of the Association Between Ct Value of SARS-CoV-2 PCR with Disease Progression and Mortality
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Methods: Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-related symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for mechanical ventilation (MV), and mortality) were reviewed retrospectively. Results: 117 patients were included in the study. The mean Ct value was 22.37±4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24; there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and ≥23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion: Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID-19 patients in this presented study.
- 22 May 2022
- Published by Akdeniz University in Akdeniz Medical Journal
The effect of intubation type and place of intubation on the development of ventilator-associated pneumonia
Amaç: Çalışmamızda entübasyon türünün (elektif veya acil) ve entübasyonun yapıldığı ortamın, ventilatör ilişkili pnömoni (VİP) gelişimi üzerine etkisinin incelenmesi amaçlanmıştır. Yöntem: 1 Şubat 2019 ve 28 Şubat 2020 tarihleri arasında VİP tanısı almış, erişkin hastalar çalışmaya alındı. Yatış nedeni, entübasyon türü (elektif, acil), entübasyonun yapıldığı yer (ambulans, acil servis, yatan hasta servisi, yoğun bakım, ameliyathane), VİP gelişene kadar geçen süre ve mortalite durumları retrospektif olarak incelendi. Bulgular: Çalışmaya 180 VİP tanılı hasta dahil edildi. Hastaların %55’ ine acil entübasyon, %45’ ine elektif entübasyon yapıldığı saptandı. Entübasyon sonrası VİP gelişimine kadar geçen ortalama süre 7,9 ± 5,9 gündü. Acil entübasyonlarda VİP gelişimine kadar geçen süre elektif entübasyonlara göre daha kısa idi (sırasıyla 6.8± 4.58 vs 9.1± 7.09 gün, p=0.023). Hastaların %33.9’unun yoğun bakımda, %26.7’ sının acil serviste, %17.2’sinin ameliyat öncesinde, %11.7’sinin yatan hasta servisinde ve %10.6’sının hastaneye getirilmeden önce entübe edildiği görüldü. 7 gün mortalite %20, 14 gün mortalite %36.7, 30 gün mortalite %46.7 olarak saptandı. Kaba mortalite ve entübasyonun yapıldığı yer arasında istatiksel anlamlı ilişki saptanmadı (p=0.366). Acil entübasyon yapılan hastalarda VİP sonrası 7, 14 ve 30 gün mortalite oranlarının elektif entübasyona göre daha fazla olduğu saptandı. Sonuç: Acil entübasyonlarda elektiflere göre VİP gelişme süresinin daha kısa olduğu (p=0,009) ve tüm nedenlere bağlı mortalitenin istatistiksel anlamlı fark olmasa da acil entübasyon yapılanlarda elektif entübasyon yapılanlara göre daha fazla olduğu saptandı. Enfeksiyon kontrol önlemlerinin acil entübasyonlarda tam uygulanamamasının bu sonuca neden olduğu düşünüldü.
- 22 May 2022
- Published by Akdeniz University in Akdeniz Medical Journal
The effect of intubation type and place of intubation on the development of ventilator-associated pneumonia
Amaç: Çalışmamızda entübasyon türünün (elektif veya acil) ve entübasyonun yapıldığı ortamın, ventilatör ilişkili pnömoni (VİP) gelişimi üzerine etkisinin incelenmesi amaçlanmıştır. Yöntem: 1 Şubat 2019 ve 28 Şubat 2020 tarihleri arasında VİP tanısı almış, erişkin hastalar çalışmaya alındı. Yatış nedeni, entübasyon türü (elektif, acil), entübasyonun yapıldığı yer (ambulans, acil servis, yatan hasta servisi, yoğun bakım, ameliyathane), VİP gelişene kadar geçen süre ve mortalite durumları retrospektif olarak incelendi. Bulgular: Çalışmaya 180 VİP tanılı hasta dahil edildi. Hastaların %55’ ine acil entübasyon, %45’ ine elektif entübasyon yapıldığı saptandı. Entübasyon sonrası VİP gelişimine kadar geçen ortalama süre 7,9 ± 5,9 gündü. Acil entübasyonlarda VİP gelişimine kadar geçen süre elektif entübasyonlara göre daha kısa idi (sırasıyla 6.8± 4.58 vs 9.1± 7.09 gün, p=0.023). Hastaların %33.9’unun yoğun bakımda, %26.7’ sının acil serviste, %17.2’sinin ameliyat öncesinde, %11.7’sinin yatan hasta servisinde ve %10.6’sının hastaneye getirilmeden önce entübe edildiği görüldü. 7 gün mortalite %20, 14 gün mortalite %36.7, 30 gün mortalite %46.7 olarak saptandı. Kaba mortalite ve entübasyonun yapıldığı yer arasında istatiksel anlamlı ilişki saptanmadı (p=0.366). Acil entübasyon yapılan hastalarda VİP sonrası 7, 14 ve 30 gün mortalite oranlarının elektif entübasyona göre daha fazla olduğu saptandı. Sonuç: Acil entübasyonlarda elektiflere göre VİP gelişme süresinin daha kısa olduğu (p=0,009) ve tüm nedenlere bağlı mortalitenin istatistiksel anlamlı fark olmasa da acil entübasyon yapılanlarda elektif entübasyon yapılanlara göre daha fazla olduğu saptandı. Enfeksiyon kontrol önlemlerinin acil entübasyonlarda tam uygulanamamasının bu sonuca neden olduğu düşünüldü.
- Open Access
- 13 December 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (6) , 2835-2849
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients
Background/aim: As the experience has increased regarding SARS-CoV-2 in time, treatment trends have changed since the beginning of the pandemic. This study aimed to compare the outcomes of different treatment modalities for inpatients in a tertiary pandemic Materials and methods: Individuals aged 18 years and above who tested positive for SARS-CoV-2 in PCR with presenting COVIDrelated radiological findings, hospitalized for at least 3 days, and completed follow-up between March 15, 2020 and November 30, 2020 were included in the study. Patients' data were reviewed retrospectively. Seven treatment groups based on the single or combined use of hydroxychloroquine, oseltamivir, favipiravir, and remdesivir were formed and compared in terms of mortality, survival, length of hospital stay, need for intensive care, and mechanical ventilation. Results: A total of 321 patients were included in the study. The length of hospital stay, the need for intensive care, and mechanical ventilation were lower in Group 1 (hydroxychloroquine) and Group 2 (hydroxychloroquine + oseltamivir) compared to the other groups (p < 0.05). No significant difference was determined in survival between treatment groups. Analysis of prognostic factors affecting overall survival revealed that the need for intensive care and mechanical ventilation increased mortality [11.1 times (p < 0.001) and 6.48 times (p < 0.001), respectively]. Conclusion: No significant difference was determined between different treatment protocols in terms of their impact on survival. To end the COVID-19 pandemic, there is an urgent need to develop highly efficient, rapid-acting, and orally available antiviral drugs.
- 13 December 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (6) , 2835-2849
Open AccessRetrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients
Background/aim: As the experience has increased regarding SARS-CoV-2 in time, treatment trends have changed since the beginning of the pandemic. This study aimed to compare the outcomes of different treatment modalities for inpatients in a tertiary pandemic Materials and methods: Individuals aged 18 years and above who tested positive for SARS-CoV-2 in PCR with presenting COVIDrelated radiological findings, hospitalized for at least 3 days, and completed follow-up between March 15, 2020 and November 30, 2020 were included in the study. Patients' data were reviewed retrospectively. Seven treatment groups based on the single or combined use of hydroxychloroquine, oseltamivir, favipiravir, and remdesivir were formed and compared in terms of mortality, survival, length of hospital stay, need for intensive care, and mechanical ventilation. Results: A total of 321 patients were included in the study. The length of hospital stay, the need for intensive care, and mechanical ventilation were lower in Group 1 (hydroxychloroquine) and Group 2 (hydroxychloroquine + oseltamivir) compared to the other groups (p < 0.05). No significant difference was determined in survival between treatment groups. Analysis of prognostic factors affecting overall survival revealed that the need for intensive care and mechanical ventilation increased mortality [11.1 times (p < 0.001) and 6.48 times (p < 0.001), respectively]. Conclusion: No significant difference was determined between different treatment protocols in terms of their impact on survival. To end the COVID-19 pandemic, there is an urgent need to develop highly efficient, rapid-acting, and orally available antiviral drugs.
- 19 November 2021
- Published by Academician Publishing
COVID-19 ve Kanser